Mostrar el registro sencillo del ítem
dc.contributor.author | Sanz González, Alba | |
dc.contributor.author | Cózar Castellano, Irene | |
dc.contributor.author | Broca, Christophe | |
dc.contributor.author | Sabatier, Julia | |
dc.contributor.author | Acosta Crespo, Gerardo A. | |
dc.contributor.author | Royo, Miriam | |
dc.contributor.author | Hernándo Muñoz, Carla | |
dc.contributor.author | Torroba, Tomás | |
dc.contributor.author | Perdomo Hernández, Germán | |
dc.contributor.author | Merino Antolín, Beatriz | |
dc.date.accessioned | 2023-08-28T09:18:12Z | |
dc.date.available | 2023-08-28T09:18:12Z | |
dc.date.issued | 2023 | |
dc.identifier.citation | Diabetes, Obesity and Metabolism, 2023. | es |
dc.identifier.issn | 1462-8902 | es |
dc.identifier.uri | https://uvadoc.uva.es/handle/10324/61166 | |
dc.description | Producción Científica | es |
dc.description.abstract | Aim:To investigate the use of synthetic preimplantation factor (sPIF) as a potentialtherapeutic tool for improving glucose-stimulated insulin secretion (GSIS), glucose tol-erance and insulin sensitivity in the setting of diabetes.Materials and Methods:We used a preclinical murine model of type 2 diabetes(T2D) induced by high-fat diet (HFD) feeding for 12 weeks. Saline or sPIF (1 mg/kg/day) was administered to mice by subcutaneously implanted osmotic mini-pumps for25 days. Glucose tolerance, circulating insulin and C-peptide levels, and GSIS wereassessed. In addition,β-cells (Min-6) were used to test the effects of sPIF on GSISand insulin-degrading enzyme (IDE) activity in vitro. The effect of sPIF on GSIS wasalso tested in human islets.Results:GSIS was enhanced 2-fold by sPIF in human islets ex vivo. Furthermore, con-tinuous administration of sPIF to HFD mice increased circulating levels of insulin andimproved glucose tolerance, independently of hepatic insulin clearance. Of note,islets isolated from mice treated with sPIF exhibited restoredβ-cell function. Finally,genetic (shRNA-IDE) or pharmacological (6bK) inactivation of IDE in Min-6 abolished | es |
dc.format.mimetype | application/pdf | es |
dc.language.iso | eng | es |
dc.publisher | Wiley | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject.classification | Antidiabetic drug | es |
dc.subject.classification | Insulin | es |
dc.subject.classification | Insulina | es |
dc.subject.classification | Glucose | es |
dc.subject.classification | Glucosa | es |
dc.title | Pharmacological activation of insulin‐degrading enzyme improves insulin secretion and glucose tolerance in diet‐induced obese mice | es |
dc.type | info:eu-repo/semantics/article | es |
dc.rights.holder | © 2023 The Author(s) | es |
dc.identifier.doi | 10.1111/dom.15225 | es |
dc.relation.publisherversion | https://dom-pubs.onlinelibrary.wiley.com/doi/full/10.1111/dom.15225?af=R | es |
dc.identifier.publicationtitle | Diabetes, Obesity and Metabolism | es |
dc.peerreviewed | SI | es |
dc.description.project | “la Caixa”Foundation (Grant/Award Number:LCF/PR/PR18/51130007) | es |
dc.description.project | Ministerio de Ciencia y Universidades (PID2019-110496RB-C21 y PID2019-110496RB-C22) | es |
dc.description.project | Generalitat de Catalunya (2017SGR1439) | es |
dc.description.project | CIBERBBN - financiado por el Instituto de Salud Carlos III (ISCIII) y FEDER (CB06-01-0074) | es |
dc.description.project | Junta de Castilla y León (Programa Estratégico del Instituto de Biología y Genética Molecular (IBGM)) (Ref. CLU-2019-02) | es |
dc.description.project | Junta de Castilla y León y el Fondo Social Europeo (ORDERDU/1508/2020) | es |
dc.identifier.essn | 1463-1326 | es |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.type.hasVersion | info:eu-repo/semantics/publishedVersion | es |
dc.subject.unesco | 23 Química | es |
dc.subject.unesco | 2302 Bioquímica | es |
Ficheros en el ítem
Este ítem aparece en la(s) siguiente(s) colección(ones)
![Attribution-NonCommercial-NoDerivatives 4.0 Internacional](/themes/Mirage2//images/creativecommons/cc-by-nc-nd.png)